Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
United States Isabella Ciccone Renato Mantegazza Neuromuscular Diseases Department European Academy Of Neurology Muscular Dystrophy Association Clinical Scientific Conference
Source: ajmc.com